

I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on September 22, 2006

PATENT
Attorney Docket No.: 082368-001100US
Client Reference No.: M3-A0201P-US

TOWNSEND and TOWNSEND and CREW LLP

By: /Aaron Hokamura/

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MASAI and TAMAI

Application No.: 10/507,275

Filed: March 12, 2003

For: CDC7-ASK KINASE COMPLEX,
SUBSTRATES OF THE KINASE
COMPLEX, SPECIFIC ANTIBODIES
TO THE SUBSTRATES, AND
SCREENING METHODS USING THE
SAME TO SCREEN FOR COMPOUNDS
COMPRISING CDC7-ASK KINASE
INHIBITORY ABILITY

Confirmation No.:

Examiner:

Art Unit:

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. A copy of reference AU is provided. Copies of references AI-AT are not provided since they were cited in an International Search Report in a corresponding application, and, as such, should have been provided directly by the WIPO under the exchange program between the USPTO, the EPO and the JPO. A copy of the Search Report is attached.

References AI, AK and AL are not in the English language. References AI and AL are categorized as "Y" documents on the attached International Search Report. Reference AK is categorized as an "X" document on the attached International Search Report.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

/Aaron T. Hokamura/

Aaron T. Hokamura
Reg. No. 51,710

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
ATH:ath
00675283 v1

Substitute for form 1448A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/507,275
		Filing Date	March 12, 2003
		First Named Inventor	Masai, Hisao
		Art Unit	
		Examiner Name	
Sheet 1	of 2	Attorney Docket Number	082368-001100US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	† ⁵
		Country Code ³	Number ⁴	Kind Code ⁶ (if known)				
	AJ	WO	01/11367	A1	02-15-2001	Medical and Biological Laboratories Co., Ltd		<input type="checkbox"/>
	AJ	EP	1184665	A1	03-06-2002	Medical and Biological Laboratories Co., Ltd		<input type="checkbox"/>
	AK	JP	00-165719	A	09-21-1985	Ainomoto Co., Inc.		<input type="checkbox"/>
	AL	JP	2001-161398	A	06-19-2001	Medical and Biological Laboratories Co., Ltd		<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60875283 v1

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/507,275
		Filing Date	March 12, 2003
		First Named Inventor	Masai, Hisao
		Art Unit	
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	062368-001100US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AM	ISHIMI, Y. et al.; "Biochemical activities associated with mouse Mcm2 protein"; <u>J. Biol. Chem.</u> 276(46):42744-42752 (November 16, 2001)	<input type="checkbox"/>
	AN	KIMURA, H. et al.; "Mouse MCM proteins: complex formation and transportation to the nucleus"; <u>Genes Cells</u> 1(11):977-993 (November 1996)	<input type="checkbox"/>
	AO	MASAI, H. et al.; "Human Cdc7-related kinase complex. In vitro phosphorylation of MCM by concerted actions of Cdk5 and Cdc7 and that of a critical threonine residue of Cdc7 by Cdk5"; <u>J. Biol. Chem.</u> 275(37):29042-29052 (September 15, 2000)	<input type="checkbox"/>
	AP	OHMI, K. et al.; "Induction of giant endothelial cells in culture by K-252a, a protein kinase inhibitor"; <u>Jpn. J. Pharmacol.</u> 63(2):195-202 (October 1993)	<input type="checkbox"/>
	AQ	SUZUKI, S. et al.; "Enzyme-linked immunosorbent assay for distinct cyclin-dependent kinase activities using phosphorylation-site-specific anti-pRB monoclonal antibodies"; <u>Anal. Biochem.</u> 301(1):65-74 (February 2002)	<input type="checkbox"/>
	AR	TODOROV, I. T. et al.; "A human nuclear protein with sequence homology to a family of early S phase proteins is required for entry into S phase and for cell division"; <u>J. Cell. Sci.</u> 107(Pt 1):253-265 (January 1994)	<input type="checkbox"/>
	AS	WARN-CRAMER, B. J. et al.; "Characterization of the mitogen-activated protein kinase phosphorylation sites on the connexin-43 gap junction protein"; <u>J. Biol. Chem.</u> 271(7):3779-3786 (February 16, 1996)	<input type="checkbox"/>
	AT	ZHANG, Y. et al.; "Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II"; <u>J. Biol. Chem.</u> 269(49):31034-31040 (December 9, 1994)	<input type="checkbox"/>
	AU	DATABASE; Geneseq Accession No. AD019248; "Human PRO polypeptide #90"; August 12, 2004	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.